10-Q: Aardvark Therapeutics Reports Wider Losses, Delays Key Trial Data

Aardvark Therapeutics, a clinical-stage biopharmaceutical company, reported significantly increased net losses and cash burn for Q2 2025, alongside a delay in topline data for its lead PWS drug candidate, ARD-101.

Summary

• Aardvark Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $14.4 million for the three months ended June 30, 2025, up from $5.4 million in the prior year period.
• The net loss for the six months ended June 30, 2025, was $23.7 million, compared to $7.6 million for the same period in 2024.
• Research and development (R&D) expenses increased to $13.1 million for Q2 2025, a significant rise from $4.0 million in Q2 2024, primarily due to increased external costs for CMC, clinical, and toxicology studies related to ARD-101.
• General and administrative (G&A) expenses also increased to $2.7 million for Q2 2025, up from $2.0 million in Q2 2024, driven by increased headcount and public company operational costs.
• The company initiated a Phase 3 HERO clinical trial for its lead product candidate, ARD-101, for hyperphagia associated with Prader-Willi Syndrome (PWS) in December 2024, with enrollment starting in Q2 2025.
• A protocol amendment was submitted in August 2025 to broaden enrollment criteria for the HERO trial, leading to a revised anticipated topline data availability in Q3 2026.
• Aardvark plans to initiate a Phase 2 HONOR clinical trial for ARD-101 in hypothalamic obesity (HO) in H2 2025, with topline data expected in H2 2026.
• The company is substituting its previously planned EMPOWER trial for ARD-201 with two new Phase 2 trials: POWER (H2 2025 initiation) focusing on preventing weight regain after GLP-1RA discontinuation, and STRENGTH (H1 2026 initiation) exploring additive effects with GLP-1RA therapy.
• New preclinical data for ARD-201 (a fixed-dose combination of ARD-101 and a DPP-4 inhibitor) demonstrated significant weight loss (-18.8% +/2.1% at 30 days) in a high-fat diet mouse model and improved weight maintenance after GLP-1RA discontinuation.
• As of June 30, 2025, cash, cash equivalents, and short-term investments totaled $141.8 million, which the company believes is sufficient to fund operations into 2027.
• The company completed its initial public offering (IPO) in February 2025, raising approximately $87.5 million in net proceeds.
• A material weakness in internal control over financial reporting was identified, related to a lack of controls, segregation of duties, and formalized processes, with remediation efforts initiated in late 2024.

Sentiment

Score: 3

Explanation: The company reported significantly increased losses and cash burn, and a delay in key clinical trial data for its lead program. While the recent IPO provides a cash runway into 2027, the operational performance shows increasing expenses without revenue. The strategic pipeline expansion is positive, but the delay in the lead program's data readout and the ongoing need for substantial future funding are significant concerns, leading to a negative sentiment.

Positives

• The company maintains a strong cash position of $141.8 million as of June 30, 2025, following its successful IPO in February 2025, providing a projected cash runway into 2027.
• Progress in the clinical pipeline includes the initiation of a pivotal Phase 3 HERO trial for ARD-101 in PWS and plans to initiate two new Phase 2 trials (POWER and STRENGTH) for ARD-201 in obesity-related conditions.
• New preclinical data for ARD-201 demonstrated significant weight loss and improved weight maintenance in mouse models, supporting the strategic shift to new trial designs.
• The company has aligned with the FDA on the protocol for the potentially pivotal Phase 3 HERO trial, indicating regulatory engagement and clarity for the lead program.
• The expansion of enrollment criteria for the HERO trial to include patients under 13 years of age and remove certain exclusion criteria could broaden the eligible patient population and market opportunity for ARD-101.

Negatives

• Net loss significantly increased to $14.4 million for Q2 2025 and $23.7 million for the six months ended June 30, 2025, indicating a higher burn rate as clinical development accelerates.
• Research and development expenses rose substantially, reflecting increased costs associated with ongoing clinical trials and manufacturing, contributing to the wider losses.
• Topline data for the Phase 3 HERO clinical trial for ARD-101 in PWS is now anticipated in Q3 2026, representing a delay from previous expectations.
• A material weakness in internal control over financial reporting was identified as of December 31, 2024, and remains un-remediated as of June 30, 2025, posing risks to financial reporting accuracy.
• The company has incurred significant accumulated deficit of $82.0 million as of June 30, 2025, and does not expect to generate revenue from product sales for several years, if ever.
• Unreimbursed costs and a convertible promissory note from related party Aardwolf Therapeutics, Inc., totaling $1.4 million and $1.0 million respectively, have been deemed uncollectible and written off.

Risks

• The company has a limited operating history and no products approved for commercial sale, making it difficult to evaluate future viability.
• Substantial additional financing will be required to achieve goals; failure to obtain could force delays or termination of product development programs.
• Business is heavily dependent on the successful development, regulatory approval, and commercialization of the lead product candidate, ARD-101.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no guarantee of success.
• Preclinical and clinical drug development is expensive, with uncertain timelines and outcomes; earlier results may not predict future trial results.
• Disorders like PWS and HO have low prevalence, making patient identification and enrollment for clinical trials difficult and potentially causing delays.
• Clinical trials may fail to demonstrate safety and efficacy, or serious adverse events may be identified, leading to delays, increased costs, or abandonment of development.
• Reliance on third parties for preclinical studies, clinical trials, and manufacturing introduces risks of non-performance, delays, increased costs, or regulatory non-compliance.
• Inability to obtain, maintain, and enforce intellectual property protection could allow competitors to commercialize similar products.
• The identified material weakness in internal control over financial reporting could lead to inaccurate or untimely financial reporting and adversely affect investor confidence.
• The company faces substantial competition from major pharmaceutical and biotechnology companies, which may result in smaller commercial opportunities.
• Interim and preliminary clinical trial results are subject to change and may differ materially from final data.
• Limited resources may be expended on product candidates or indications that prove less profitable or successful.
• Obtaining regulatory approval in one jurisdiction does not guarantee approval in others, and foreign data may not be accepted by the FDA.
• Ongoing regulatory obligations and continued review post-approval may result in significant additional expense and potential restrictions.
• Disruptions at the FDA and other government agencies due to funding shortages or global health concerns could hinder timely product development and commercialization.
• Changes in product candidate manufacturing or formulation may result in additional costs or delays.
• The company may not be successful in identifying or discovering additional product candidates in the future.
• Orphan Drug Designation may not be maintained or effectively protect ARD-101 from competition.
• Breakthrough Therapy or other expedited regulatory designations may not lead to faster development or approval.
• Collaborations with third parties may not be successful, and conflicts could arise.
• Sharing trade secrets with third parties increases the risk of misappropriation or disclosure.
• Operations of suppliers, particularly those sourcing raw materials outside the U.S., are subject to additional risks beyond the company's control.
• Claims challenging the inventorship or ownership of patents and other intellectual property could arise.
• Claims of wrongful hiring or use of confidential information from competitors could lead to litigation.
• Inability to license or acquire necessary third-party intellectual property could hinder development.
• Intellectual property agreements may be subject to disagreements over interpretation or retained rights by licensors.
• The scope of patent protection obtained may be insufficient or lost, affecting competitive advantage.
• Lawsuits to protect or enforce patents are expensive, time-consuming, and may be unsuccessful.
• Changes in patent law could diminish the value of patents.
• Trademarks and trade names may not be adequately protected, impacting brand recognition.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Relationships with customers, physicians, and third-party payors are subject to complex healthcare fraud and abuse laws.
• Healthcare reform measures and governmental scrutiny over drug pricing may increase costs and affect prices.
• Changing regulatory environments, including foreign data protection laws like GDPR, could negatively impact business.
• Subject to U.S. and foreign anti-corruption, anti-money laundering, export control, and sanctions laws.
• Failure to comply with environmental, health, and safety laws could result in fines or penalties.
• Difficulty monitoring and responding to evolving sustainability (ESG) expectations may impose costs or reputational harm.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Significant disruptions of information technology systems or data security incidents could cause harm.
• Operations are concentrated in California, exposing the company to natural disaster risks.
• International expansion exposes the company to business, regulatory, political, operational, financial, and economic risks.
• Stock price may be volatile, and quarterly/annual operating results may fluctuate significantly.
• No dividends are anticipated in the foreseeable future.
• The board of directors can issue preferred stock without stockholder approval, potentially diluting common stockholders.
• Principal stockholders and management own a significant percentage of common stock, enabling control over stockholder approval matters.
• Anti-takeover provisions in charter documents and Delaware law could prevent or delay acquisitions.
• Exclusive forum provisions for disputes could limit stockholders' ability to obtain a favorable judicial forum.
• Recent and future changes to tax laws could materially adversely affect the company.
• Securities litigation is a risk, which is expensive and could divert management attention.
• Operating as a public company incurs significant increased costs and requires substantial management time for compliance.
• Future issuance of equity or convertible debt securities would dilute share capital.
• Sales of a substantial number of shares by existing stockholders could cause the stock price to fall.
• Techniques employed by short sellers may drive down the market price.
• Status as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
• Lack of research coverage by securities or industry analysts could negatively impact stock price and trading volume.
• Failure to meet Nasdaq's continued listing requirements could result in delisting.
• Unfavorable global economic or political conditions could adversely affect the business.

Future Outlook

The company expects its expenses and operating losses to increase substantially for the foreseeable future as it continues development, seeks regulatory approval, and potentially commercializes ARD-101 and other product candidates. It anticipates needing substantial additional funding beyond its current cash resources, which are projected to fund operations into 2027. The company plans to finance future cash needs through equity offerings, debt financings, or collaborations. It does not expect to generate product sales revenue for many years, if ever, and intends to build sales, marketing, and distribution capabilities over time.

Management Comments

• Believe existing cash, cash equivalents, and short-term investments of $141.8 million as of June 30, 2025, will be sufficient to continue as a going concern for at least one year.
• Will be required to raise additional capital and plans to finance cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses, and similar arrangements.
• Expect expenses and operating losses to increase substantially for the foreseeable future as development, regulatory approval, and potential commercialization of product candidates continue.
• Do not expect to generate any revenue from product sales until successful completion of development and regulatory approval for one or more product candidates, which is expected to take a number of years and may never occur.
• Do not own or operate, and currently have no plans to establish, any manufacturing facilities, relying on third parties for manufacturing clinical and commercial supplies.
• Intend to build necessary sales, marketing, and commercialization capabilities and infrastructure over time as product candidates advance through clinical development.
• Do not believe that inflation has had a material effect on results of operations during the periods presented.
• Disclosure controls and procedures were not effective at the reasonable level of assurance as of June 30, 2025, due to a material weakness in internal control over financial reporting.
• Began steps in late 2024 to remediate the material weakness through hiring additional experienced accounting and financial reporting personnel, formalizing internal controls, and implementing a new enterprise resource planning system.

Industry Context

Aardvark Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on novel small-molecule therapeutics for metabolic diseases by targeting Bitter Taste Receptors (TAS2Rs). This is a rapidly evolving field with significant unmet medical needs. The company faces competition in Prader-Willi Syndrome (PWS) from Soleno Therapeutics (with an approved treatment, VYKAT XR) and other companies like Acadia Pharmaceuticals and Rhythm Pharmaceuticals in development. For hypothalamic obesity (HO), Rhythm Pharmaceuticals has a late-stage therapeutic candidate. In the broader obesity and obesity-related conditions market, Aardvark competes with major pharmaceutical companies and independent biotechnology firms including Eli Lilly, Novo Nordisk, Roche, Pfizer, AstraZeneca, Boehringer Ingelheim, Amgen, Zealand Pharma, Viking Therapeutics, Altimmune, Terns Pharmaceuticals, Merck, and Structure Therapeutics. The industry is characterized by rapid technological change, fierce competition, and strong intellectual property defense. The company also notes exposure to macroeconomic trends such as geopolitical conflicts, banking disruptions, and inflationary pressures.

Comparison to Industry Standards

• For Prader-Willi Syndrome (PWS), Soleno Therapeutics' VYKAT XR is the only approved treatment for hyperphagia, setting a benchmark for market entry.
• Other competitors in PWS include therapeutic candidates in development from Acadia Pharmaceuticals and Rhythm Pharmaceuticals.
• For hypothalamic obesity (HO), Rhythm Pharmaceuticals has a therapeutic candidate in late-stage development.
• In the broader obesity and obesity-related conditions market, Aardvark's ARD-201 program competes with a wide array of established and emerging players, including Eli Lilly, Novo Nordisk, Roche, Pfizer, AstraZeneca, Boehringer Ingelheim, Amgen, Zealand Pharma, Viking Therapeutics, Altimmune, Terns Pharmaceuticals, Merck, and Structure Therapeutics, many of whom have significantly greater financial resources and expertise.

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that, in management's opinion, would have a material adverse effect on the business, financial condition, or results of operations.
• May become subject to claims or suits arising in the ordinary course of business.
• Has entered into indemnification agreements with officers and members of the board of directors, which may require the company to indemnify them against certain liabilities.

Related Party Transactions

• Family members of the Chief Executive Officer are investors, owning 1,975,323 shares of common stock as of June 30, 2025.
• The Chief Executive Officer is a member of the board of directors of Aardwolf Therapeutics, Inc.
• Unreimbursed costs of $1.4 million incurred on behalf of Aardwolf Therapeutics, Inc. (from a Transition Services Agreement that expired in May 2024) have been deemed uncollectible and fully written off.
• A convertible promissory note of $1.0 million issued by Aardwolf Therapeutics, Inc. to the company in August 2022 has also been deemed uncollectible and written off.
• Aardwolf Therapeutics, Inc. is considered a variable interest entity (VIE) but is not consolidated in the company's financial statements.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and stock price volatility due to increased losses and clinical trial delays, despite a strong current cash position.
• Employees benefit from new equity incentive plans (2025 Plan, 2025 Inducement Plan, ESPP) designed to attract and retain talent, but the company acknowledges intense competition for qualified personnel.
• Future patients could benefit from novel therapeutics for metabolic diseases like PWS, HO, and obesity, pending successful clinical development and regulatory approval.
• Third-party contractors (CROs, CMOs) remain critical for R&D and manufacturing, with the company's reliance on them posing risks if they fail to perform or comply with regulations.
• Regulatory bodies will continue to scrutinize the company's clinical trials, manufacturing processes, and financial reporting, particularly given the identified material weakness in internal controls.

Next Steps

• Continue development of ARD-101 and other product candidates.
• Seek regulatory approval for product candidates.
• Potentially commercialize ARD-101 and other product candidates.
• Discover and develop additional product candidates.
• Conduct ongoing and planned clinical trials and preclinical studies.
• Utilize third parties to manufacture ARD-101 and other product candidates.
• Hire additional personnel, including clinical, regulatory, quality, management, and scientific staff.
• Maintain, expand, and protect intellectual property.
• Implement operational, financial, and management information systems.
• Build sales, marketing, and commercialization capabilities.
• Complete the Phase 3 HERO clinical trial for ARD-101 in PWS, with topline data anticipated in Q3 2026.
• Initiate Phase 2 HONOR clinical trial for ARD-101 in HO in H2 2025, with topline data anticipated in H2 2026.
• Initiate Phase 2 POWER trial for ARD-201 in H2 2025.
• Initiate Phase 2 STRENGTH trial for ARD-201 in H1 2026.
• Remediate the identified material weakness in internal control over financial reporting by hiring additional experienced accounting and financial reporting personnel, formalizing internal controls, and implementing a new ERP system.

Key Dates

Recommendation

Aardvark Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline targeting significant unmet medical needs in metabolic diseases. The recent IPO has provided a substantial cash runway into 2027, which is crucial for funding its extensive R&D activities. However, the company reported significantly increased net losses and cash burn, reflecting the high costs of clinical development. The delay in topline data for the pivotal HERO trial for ARD-101, while explained by a strategic broadening of enrollment criteria, introduces further uncertainty and extends the timeline to potential commercialization. The identified material weakness in internal controls is also a concern that needs effective remediation. Given the early stage of its pipeline, the inherent risks of drug development, and the increasing operational costs, a 'Hold' recommendation is appropriate. Investors should monitor the progress of clinical trials, particularly the HERO trial, the effectiveness of the internal control remediation, and any future capital raising activities. The long-term potential is significant if clinical milestones are met, but the near-term financial performance and operational risks warrant caution.

Keywords

Biopharmaceutical, Clinical-stage, Metabolic Diseases, Prader-Willi Syndrome, Hyperphagia, Hypothalamic Obesity, Obesity, ARD-101, ARD-201, TAS2R, Drug Development, Clinical Trials, SEC Filing, 10-Q, Biotech, Pharmaceutical, Orphan Drug, IPO, Nasdaq